317 related articles for article (PubMed ID: 33745879)
1. The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Singh S; Numan A; Maddiboyina B; Arora S; Riadi Y; Md S; Alhakamy NA; Kesharwani P
Drug Discov Today; 2021 Jul; 26(7):1721-1727. PubMed ID: 33745879
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
3. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
4. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
Michaels E; Chen N; Nanda R
Clin Breast Cancer; 2024 Jun; 24(4):263-270. PubMed ID: 38582617
[TBL] [Abstract][Full Text] [Related]
5. Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE; Tolaney SM
J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
[TBL] [Abstract][Full Text] [Related]
6. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
[TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
Hall PE; Schmid P
Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
[No Abstract] [Full Text] [Related]
8. Immunotherapeutic interventions of Triple Negative Breast Cancer.
Li Z; Qiu Y; Lu W; Jiang Y; Wang J
J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
10. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
11. Single peptides and combination modalities for triple negative breast cancer.
Razazan A; Behravan J
J Cell Physiol; 2020 May; 235(5):4089-4108. PubMed ID: 31642059
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
13. Tumor immune microenvironment and systemic response in breast cancer.
Kawaguchi K; Maeshima Y; Toi M
Med Oncol; 2022 Sep; 39(12):208. PubMed ID: 36175677
[TBL] [Abstract][Full Text] [Related]
14. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor.
Xu J; Gan C; Yu S; Yao S; Li W; Cheng H
Clin Breast Cancer; 2024 Feb; 24(2):e91-e102. PubMed ID: 38016911
[TBL] [Abstract][Full Text] [Related]
16. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer.
Licata L; Dieci MV; De Angelis C; Marchiò C; Miglietta F; Cortesi L; Fabi A; Schmid P; Cortes J; Pusztai L; Bianchini G; Curigliano G
Cancer Treat Rev; 2024 Jul; 128():102762. PubMed ID: 38776613
[TBL] [Abstract][Full Text] [Related]
17. Advances in immunotherapy for triple-negative breast cancer.
Liu Y; Hu Y; Xue J; Li J; Yi J; Bu J; Zhang Z; Qiu P; Gu X
Mol Cancer; 2023 Sep; 22(1):145. PubMed ID: 37660039
[TBL] [Abstract][Full Text] [Related]
18. Triple‑negative breast cancer therapy: Current and future perspectives (Review).
Won KA; Spruck C
Int J Oncol; 2020 Dec; 57(6):1245-1261. PubMed ID: 33174058
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer.
Cejuela M; Vethencourt A; Pernas S
Curr Oncol Rep; 2022 Dec; 24(12):1801-1819. PubMed ID: 36255603
[TBL] [Abstract][Full Text] [Related]
20. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
